Clinical Study
Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
Table 1
Characteristics of patients enrolled in the database.
| | Parameter of interest | Total
|
| | Years of birth | 1980–2011 | | Ethnicity: caucasian (%) | 100 | | Factor concentrates used () | | | pdFVIII | 177 | | rFVIII | 111 | | Median (min–max) single dose FVIII (IU/kg/bw) | 35 (15–100) | | Median (min–max) weekly substitution intervals | 3 (1–3) | | Persistent high-titer inhibitor | 71/288 (24.7%) | | pdFVIII* | 29/177 (16.38%) | | rFVIII | 41/111 (36.9%) | | (i) First generation: | 9/46 (19.5%) | | CHO; full-length; human albumin | 8/38 (12.5%) | | BHK; full-length; human albumin | 1/8 (21.0%) | | (ii) Second generation: | 32/63 (50.7%) | | CHO; B-domain-deleted | 5/14 (35.7%) | | BHK; full-length; sucrose | 27/49 (55.1%) | | (iii) Third generation | 1/2 | | CHO; full-length; trehalose | 1/2 (50.0%) | | Indications for intensified treatment | | | Total: number | 28 | | Neonatal ICH | 6 | | Cephalhematoma | 6 | | Liver rupture | 1 | | Head/spinal trauma | 4 | | Knee or ankle bleed | 4 | | Tongue bleed | 4 | | Appendectomy | 1 | | Meatotomy | 1 | | Nephroblastoma surgery | 1 |
|
|
BHK: baby hamster kidney; BU: Bethesda units; CHO: Chinese hamster ovary; ICH: intracranial hemorrhage; min–max: minimum–maximum; kg bw: kilogram bodyweight; pd: plasma derived; r: recombinant.
*Beriate P (11/50: 22.0%); Hemophil M (8/39: 20.5%); Humate P (10/43: 23.0%).
|
